year 17, Issue 2 (March - April 2023)                   Iran J Med Microbiol 2023, 17(2): 128-134 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Owliaee I, Saadat N, Mahmoudvand S, Vakilimofrad H, Khazaei S, Ansari N, et al . Serum Amyloid A (SAA) as Early Diagnosis of COVID-19 Disease: A Systematic Review and Meta-Analysis. Iran J Med Microbiol 2023; 17 (2) :128-134
1- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Virology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
3- Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4- Department of Medical Library and Information Sciences, School of Paramedicine, Hamadan University of Medical Sciences, Hamadan, Iran
5- Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
6- Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
7- Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract:   (1121 Views)

Background and Aim: In December 2019, human-to-human transmission of respiratory illness (pneumonia) with fever and sputum was discovered in the respiratory tract, called COVID-19. Serum amyloid A (SAA) is an acute-phase plasma protein that is considered to be diagnostically superior to CRP in pathological conditions such as viral diseases. Therefore, the study question in this review is whether SAA as an indicator is involved in the early diagnosis of COVID disease.
Materials and Methods: To identify related studies, we systematically searched international databases, including PubMed, Scopus, Science Direct, Cochrane, Embase, Web of Science, and Google Scholar search engine, without restriction on time until June 2021. Also, the Reference list of relevant studies was reviewed separately to find all existing articles in this field. Summary standardized mean difference (SMD) was estimated using random effects meta-analysis.
Results: A total of 394 potentially relevant articles were identified from the initial search. After removing the duplicates and reading the title, abstract and full-text review, six studies were entered into the meta-analysis. There was a significant difference between the means of SSA among patients with a severe form of the disease compared to non-sever groups (SMD=-0.91, 95% CI: 1.18-1.59, -0.23) and with the control group (SMD=4.68, 95% CI: 1.18, 8.18). The Beggs and egger test results indicated no evidence of publication bias in the reported SMD.
Conclusion: The result of our work indicates that SAA might potentially be used for the early diagnosis of COVID disease, but more studies are needed.

Full-Text [PDF 617 kb]   (313 Downloads) |   |   Full-Text (HTML)  (229 Views)  
Type of Study: Meta-analysis Article | Subject: Medical Virology
Received: 2022/04/24 | Accepted: 2022/10/6 | ePublished: 2023/03/30

1. Haroun RAH, Osman WH, Eessa AM. Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity. Life Sci. 2021;269:119019. [DOI:10.1016/j.lfs.2021.119019] [PMID] [PMCID]
2. Burrell CJ, Howard CR, Murphy FA. Fenner and white's medical virology. Academic Press2016.
3. Liu SL, Wang SY, Sun YF, Jia QY, Yang CL, Cai PJ, et al. Expressions of SAA, CRP, and FERR in different severities of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(21 ):11386-94.
4. Liu Q, Dai Y, Feng M, Wang X, Liang W, Yang F. Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study. J Clin Lab Anal. 2020;34(10):e23527. [DOI:10.1002/jcla.23527]
5. World Health O. WHO Coronavirus (COVID-19) Dashboard Coronavirus (COVID-19) Dashboard [Internet].[consultado 25 Sep 2021].
6. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761-70. [DOI:10.1080/22221751.2020.1747363] [PMID] [PMCID]
7. Tufan A, Güler AA, MatuccimCerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish J Med Sci. 2020(50):620-32. [DOI:10.3906/sag-2004-168] [PMID] [PMCID]
8. Ji M, Yuan L, Shen W, Lv J, Li Y, Li M, et al. Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan, China. Epidemiol Infect. 2020;148(E94). [DOI:10.1017/S0950268820000977] [PMID] [PMCID]
9. Li H, Xiang X, Ren H, Xu L, Zhao L, Xiaoqiong C, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect. 2020;80(6):646-55. [DOI:10.1016/j.jinf.2020.03.035] [PMID] [PMCID]
10. Manunta MDI, Lamorte G, Ferrari F, Trombetta E, Tirone M, Bianco C, et al. Impact of SARS-CoV-2 infection on the recovery of peripheral blood mononuclear cells by density gradient. Sci Rep. 2021;11(1):4904. [DOI:10.1038/s41598-021-83950-2] [PMID] [PMCID]
11. Pontelli MC, Castro IA, Martins RB, Veras FP, La Serra L, Nascimento DC, et al. Infection of human lymphomononuclear cells by SARS-CoV-2. BioRxiv. 2020. [DOI:10.1101/2020.07.28.225912]
12. Witkowska-Piłaszewicz OD, Żmigrodzka M, Winnicka A, Miśkiewicz A, Strzelec K, Cywińska A. Serum amyloid A in equine health and disease. Equine Vet J. 2019;51(3):293-8. [DOI:10.1111/evj.13062] [PMID] [PMCID]
13. Chen M, Wu Y, Jia W, Yin M, Hu Z, Wang R, et al. The predictive value of serum amyloid A and Creactive protein levels for the severity of coronavirus disease 2019. Am J Transl Res. 2020;12(8):4569-75.
14. Sack GH. Serum amyloid A - a review. Mol Med. 2018;24(1):46. [DOI:10.1186/s10020-018-0047-0] [PMID] [PMCID]
15. Zhang Y, Wang D, Lin M, Sun T, Chen J, Xu J, et al. Serum amyloid A protein as a potential biomarker useful in monitoring the course of COVID-19: a retrospectively studied. 2020. [DOI:10.21203/]
16. Peters JPM, Hooft L, Grolman W, Stegeman I. Reporting Quality of Systematic Reviews and Meta-Analyses of Otorhinolaryngologic Articles Based on the PRISMA Statement. PLOS ONE. 2015;10(8):e0136540. [DOI:10.1371/journal.pone.0136540] [PMID] [PMCID]
17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629. [DOI:10.1136/bmj.315.7109.629] [PMID] [PMCID]
18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
19. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci. 2020;254:117788. [DOI:10.1016/j.lfs.2020.117788] [PMID] [PMCID]
20. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J. 1998;334(3):489-503. [DOI:10.1042/bj3340489] [PMID] [PMCID]
21. Yuki M, Aoyama R, Nakagawa M, Hirano T, Naitoh E, Kainuma D. A Clinical Investigation on Serum Amyloid A Concentration in Client-Owned Healthy and Diseased Cats in a Primary Care Animal Hospital. Veterinary Sciences [Internet]. 2020; 7(2). [DOI:10.3390/vetsci7020045] [PMID] [PMCID]
22. Cheng L, Yang J-Z, Bai W-H, Li Z-Y, Sun L-F, Yan J-J, et al. Prognostic value of serum amyloid A in patients with COVID-19. Infection. 2020;48(5):715-22. [DOI:10.1007/s15010-020-01468-7] [PMID] [PMCID]
23. Ji M, Yuan L, Shen W, Lv J, Li Y, Li M, et al. Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan, China. Epidemiol Infect. 2020;148:e94. [DOI:10.1017/S0950268820000977] [PMID] [PMCID]
24. Yip TTC, Chan JWM, Cho WCS, Yip T-T, Wang Z, Kwan T-L, et al. Protein Chip Array Profiling Analysis in Patients with Severe Acute Respiratory Syndrome Identified Serum Amyloid A Protein as a Biomarker Potentially Useful in Monitoring the Extent of Pneumonia. Clin Chem. 2005;51(1):47-55. [DOI:10.1373/clinchem.2004.031229] [PMID] [PMCID]
25. Yu Y, Liu T, Shao L, Li X, He CK, Jamal M, et al. Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study. Virulence. 2020;11(1):1569-81. [DOI:10.1080/21505594.2020.1802194] [DOI:10.1080/21505594.2020.1840108] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc